A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Advanced solid tumors
Histological or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or PCWG3 (prostate only).
At least 1 lesion accessible for biopsy in addition to the target lesion
Participants must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
You may not be if
Participants with active central nervous system (CNS) metastases, untreated CNS metastases, or with the CNS as the only site of disease are excluded (controlled brain metastases will be allowed to enroll)
Participants with carcinomatous meningitis
Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
Active, known, or suspected autoimmune disease
Uncontrolled or significant cardiovascular disease
Participants with known allergies to egg products, neomycin and tetanus toxoid.
Prior adverse reaction to tetanus toxoid- containing vaccines.